Moderna COVID-19 Vaccine Active Against Emerging Variants – MPR
In vitro neutralization studies of sera from individuals vaccinated with Moderna’s COVID-19 vaccine showed that vaccination produced neutralizing titers against key emerging variants.
In vitro neutralization studies of sera from individuals vaccinated with Moderna’s COVID-19 vaccine showed that vaccination produced neutralizing titers against key emerging variants.
Each Ingrezza Sprinkle capsule contains oral granules consisting of valbenazine, a vesicular monoamine transporter 2 inhibitor.
Dr Charles Raison, the Director of Clinical Research at the Usona Institute and Professor in the Department of Psychiatry at the University of Wisconsin–Madison, talks to…
Beqvez is a one-time AAV-based gene therapy designed to introduce in the transduced cells a functional copy of the FIX gene encoding a high-activity FIX…
MamaLift Plus is intended as an adjunct to clinician-managed outpatient care to provide neurobehavioral interventions to patients 22 years of age and older with mild…
Nogapendekin alfa inbackicept-pmin is an interleukin-15 receptor agonist.
The approval was based on data from the phase 3 VISIBLE 2 trial.
The double-blind, phase 3 study included 2 groups of patients, those who were not on positive airway pressure therapy and those who were.
PowerHeal is indicated for superficial wounds such as minor cuts, scrapes, irritations, abrasions, and blisters and is available in a variety of sizes.
A regulatory decision is expected on February 14, 2025.
The approval was based on data from the phase 3 VISIBLE 2 trial.